Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:49:01 EDT Fri 17 May 2024
Enter Symbol
or Name
USA
CA



Q:RNLX - RENALYTIX PLC SPON ADS EACH REP 2 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RNLX - Q0.30.5899·0.63930.10.5889    4.0377  0.2449May 16May 1515 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-15 07:00U:RNLXNews ReleaseRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
2024-05-09 07:00U:RNLXNews ReleaseRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
2024-04-08 07:00U:RNLXNews ReleaseRenalytix Announces Financing with Expected Size of up to $4 Million
2024-03-14 07:01U:RNLXNews ReleaseKidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
2024-02-15 07:01U:RNLXNews ReleaseRenalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
2024-02-09 09:01U:RNLXNews ReleaseRenalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2024-01-10 07:01U:RNLXNews ReleaseNew published data demonstrates KidneyIntelX ¢ „ ¢ has broad implications for winning war on chronic kidney disease
2023-11-14 07:00U:RNLXNews ReleaseRenalytix Reports Financial Results for First Quarter of Fiscal Year 2024
2023-11-07 07:01U:RNLXNews ReleaseRenalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
2023-10-06 07:00U:RNLXNews ReleaseUS Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
2023-09-28 07:01U:RNLXNews ReleaseRenalytix Reports Full Year Fiscal 2023 Results
2023-09-25 07:01U:RNLXNews ReleaseRenalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
2023-09-07 07:00U:RNLXNews ReleaseRenalytix Appoints Senior Executive Howard Doran as Chief Business Officer
2023-08-03 07:00U:RNLXNews ReleaseRenalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd
2023-07-21 07:00U:RNLXNews ReleaseRenalytix Announces Middle East Distribution Agreement with Vector Pharma
2023-07-07 07:01U:RNLXNews ReleaseLate-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions
2023-07-03 07:00U:RNLXNews ReleaseRenalytix Appoints Financial Executive Catherine Coste to its Board of Directors
2023-06-29 18:01U:RNLXNews ReleaseFDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
2023-06-15 07:00U:RNLXNews ReleaseKidneyIntelX ¢ „ ¢ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences
2023-06-09 07:01U:RNLXNews ReleaseRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2023